SCHEMBL7921137

SCHEMBL7921137

Cc1cnc2c(c1)nnn2C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.36
KEAP1 Q14145 1/20 0.36
CYP1A2 P05177 2/20 0.35
CLK1 P49759 1/20 0.35
DYRK1A Q13627 1/20 0.35
CCR1 P32246 1/20 0.34
CCR5 P51681 1/20 0.34
CCR8 P51685 1/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
PDE2A O00408 1/20 0.34
PDE10A Q9Y233 1/20 0.34
MAPT P10636 1/20 0.33
HCAR3 P49019 1/20 0.33
BRD4 O60885 1/20 0.32
RXRA P19793 3/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2B Q13224 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8259093 0.80 SLC9A1 (0.34) SLC9A1KEAP1CLK1DYRK1AMAPT
SCHEMBL3513250 0.80 HSD17B10 (0.44) SLC9A1KEAP1CLK1DYRK1AMAPT
SCHEMBL19836260 0.77 HRH3 (0.37) SLC9A1KEAP1MAPTRXRAGRIN1
SCHEMBL14820272 0.77 KDM4E (0.35) SLC9A1KEAP1MAPTRAB9AIKBKB
SCHEMBL17694869 0.77 PDE2A (0.35) SLC9A1KEAP1PDE2APDE10APDE6A
SCHEMBL14805639 0.73 KDM4E (0.35) SLC9A1KEAP1MAPTRAB9APOLB
SCHEMBL12890492 0.73 BRD4 (0.36) SLC9A1KEAP1MAPTBRD4RAB9A
SCHEMBL18193686 0.73 HSD17B10 (0.38) CYP1A2MAPTRXRAGRIN1GRIN2B
SCHEMBL12775638 0.72 ADA (0.39) SLC9A1KEAP1CYP1A2MAPTCYP3A4
SCHEMBL10238681 0.72 GRM5 (0.50) CYP1A2DYRK1ACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822119-B2 Inhibitors of lysine specific demethylase-1 CELGENE QUANTICEL RESEARCH, INC. (US) 2017-11-21 US disclosed
US-20160108046-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 CELGENE QUANTICEL RESEARCH, INC. 2016-04-21 US disclosed
WO-2016037005-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 Quanticel Pharmaceuticals, Inc. (US) 2016-03-10 WO disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed
EP-2351743-A1 BICYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2011-08-03 EP disclosed
WO-2010050445-A1 BICYCLIC COMPOUND 武田薬品工業株式会社 (JP) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB SLC9A1 1197/4885KEAP1 89/4885CYP1A2 2432/4885
US-20160108046-A1 INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 KDM1B, KDM1A, KDM3A SLC9A1 3735/4885KEAP1 251/4885CYP1A2 2311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.